The DOI matches its Crossref record; 283 of the 283 references it cites were found in a registry or an index.
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Open accessAbstract
Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in signal transduction initiated by a wide range of membrane receptors. Among the proteins in this family JAK2 has been associated with important downstream proteins, including signal transducers and activators of transcription (STATs), which in turn regulate the expression of a variety of proteins involved in induction or prevention of apoptosis. Therefore, the JAK/STAT signaling axis plays a major role in the proliferation and survival of different cancer cells, and may even be involved in resistance mechanisms against molecularly targeted drugs. Despite extensive research focused on the protein structure and mechanisms of activation of JAKs, and signal transduction through these proteins, their importance in cancer initiation and progression seem to be underestimated. This manuscript is an attempt to highlight the role of JAK proteins in cancer biology, the most recent developments in targeting JAKs, and the central role they play in intracellular cross-talks with other signaling cascades.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, H., Lee, J., He, C., Zou, M., & Xie, Z. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00202.2013 · Cited by 74
RetractedMantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“Among STATs, STAT1 and STAT2 are known as the targets of interferon activation (165).”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
MicroRNA biogenesis: coordinated cropping and dicing
Kim, V. N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1644 · Cited by 2,546
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 2×
“It has been interconnected with nuclear factor-κB (NF-κB) signaling, and they seem to co-regulate a variety of oncogenic and inflammatory genes (226).”
BackgroundThe causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
The JAK/STAT signaling pathway
Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00963 · Cited by 1,858
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 2×
“S703I Inflammatory Adenoma and Leukemia (50)”
Amir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550
The JAK-STAT Pathway at Twenty
Stark, G. R., & Darnell, J. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.013 · Cited by 1,517
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality
Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., & Akira, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3801 · Cited by 1,323 · cited 1×
“It also seems to play a crucial role in development, as knocking down STAT3 in mice has been proven to be lethal to the embryo (227).”
BackgroundCYTOKINES: COORDINATORS OF IMMUNE AND INFLAMMATORY RESPONSES
Arai, K.-I., Lee, F., Miyajima, A., Miyatake, S., Arai, N., & Yokota, T. (1990) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.59.070190.004031 · Cited by 1,318
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene
Shimoda, K., van Deursent, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, C., Quelle, F. W., Nosaka, T., Vignali, D. A. A., et al. (1996) · Nature · doi:10.1038/380630a0 · Cited by 1,278 · cited 1×
“STAT6 activation seems to be triggered mainly by IL-4 and IL-13, and the loss of these cascades has been reported to impaired T-helper 2 cell differentiation (236) and development of certain types of leukemias and lymphomas (235), respectively.”
BackgroundJAK-STAT Signaling: From Interferons to Cytokines
Schindler, C., Levy, D. E., & Decker, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700016200 · Cited by 1,258
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Förster, I., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80005-9 · Cited by 1,220
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A. A., Doherty, P. C., Grosveld, G. C., et al. (1996) · Nature · doi:10.1038/382171a0 · Cited by 1,180
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
O'Shea, J. J., Gadina, M., & Schreiber, R. D. (2002) · Cell · doi:10.1016/s0092-8674(02)00701-8 · Cited by 1,119
Görlich, D., & Mattaj, I. W. (1996) · Science · doi:10.1126/science.271.5255.1513 · Cited by 1,086
The Role of Hemocytes in Anopheles gambiae Antiplasmodial Immunity
Ramirez, J. L., Garver, L. S., Brayner, F. A., Alves, L. C., Rodrigues, J., Molina-Cruz, A., & Barillas-Mury, C. (2014) · Journal of Innate Immunity · doi:10.1159/000353765 · Cited by 1,084
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Liao, W., Lin, J.-X., & Leonard, W. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.004 · Cited by 1,075
A Big Bang model of human colorectal tumor growth
Sottoriva, A., Kang, H., Ma, Z., Graham, T. A., Salomon, M. P., Zhao, J., Marjoram, P., Siegmund, K., Press, M. F., Shibata, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3214 · Cited by 1,015
Heterogeneity in breast cancer
Polyak, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60534 · Cited by 1,006
Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., & Pfeffer, K. (1998) · Cell · doi:10.1016/s0092-8674(00)81168-x · Cited by 914
Serine phosphorylation of STATs
Decker, T., & Kovarik, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203481 · Cited by 887
Rodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Yin, L., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 853
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
SOCS3 negatively regulates IL-6 signaling in vivo
Croker, B. A., Krebs, D. L., Zhang, J.-G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Förster, I., Clausen, B. E., et al. (2003) · Nature Immunology · doi:10.1038/ni931 · Cited by 840
Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., & Struhl, K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.023 · Cited by 830 · cited 1×
“For instance, it has been shown that STAT3 directly activates miRNA-21, which in turn, downregulate PTEN, among other proteins, which is a well-known tumor suppressor gene (239, 240).”
BackgroundWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826
A Single Phosphotyrosine Residue of Stat91 Required for Gene Activation by Interferon-γ
Shuai, K., Stark, G. R., Kerr, L. M., & Darnell, J. E. (1993) · Science · doi:10.1126/science.7690989 · Cited by 802
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
Koskela, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 777
Activation of Transcription by IFN-γ: Tyrosine Phosphorylation of a 91-kD DNA Binding Protein
Shuai, K., Schindler, C., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1281555 · Cited by 775
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages
Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., Hanada, T., Takeda, K., Akira, S., Hoshijima, M., et al. (2003) · Nature Immunology · doi:10.1038/ni938 · Cited by 771
Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor
Marrero, M. B., Schieffer, B., Paxton, W. G., Heerdt, L., Berk, B. C., Delafontaine, P., & Bernstein, K. E. (1995) · Nature · doi:10.1038/375247a0 · Cited by 745
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Tofacitinib versus methotrexate in rheumatoid arthritis
Lee, E. B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J. D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G. V., Zang, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310476 · Cited by 711
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 581
Interleukin-21: a double-edged sword with therapeutic potential
Spolski, R., & Leonard, W. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4296 · Cited by 548
Blumberg, H., Conklin, D., Xu, W., Grossmann, A., Brender, T., Carollo, S., Eagan, M., Foster, D., Haldeman, B. A., Hammond, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00187-8 · Cited by 547
Growth Hormone Insensitivity Associated with a STAT5b Mutation
Kofoed, E. M., Hwa, V., Little, B., Woods, K. A., Buckway, C. K., Tsubaki, J., Pratt, K. L., Bezrodnik, L., Jasper, H., Tepper, A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022926 · Cited by 525
Nuclear targeting signal recognition: a key control point in nuclear transport?
Jans, D. A., Xiao, C.-Y., & Lam, M. H. C. (2000) · BioEssays · doi:10.1002/(sici)1521-1878(200006)22:6<532::aid-bies6>3.0.co;2-o · Cited by 519
Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation
Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S., Harris, J., Holland, S. M., Schreiber, R. D., & Casanova, J.-L. (2001) · Science · doi:10.1126/science.1061154 · Cited by 517
The chemokine SDF‐lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway
Vila‐Coro, A. J., Rodríguez‐Frade, J. M., De Ana, A. M., Moreno‐Ortíz, M. C., Martínez‐A., C., & Mellado, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.13.1699 · Cited by 506
Information networks in the mammary gland
Hennighausen, L., & Robinson, G. W. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1714 · Cited by 506
Cui, Y., Riedlinger, G., Miyoshi, K., Tang, W., Li, C., Deng, C.-X., Robinson, G. W., & Hennighausen, L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.18.8037-8047.2004 · Cited by 497
Nosaka, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4754 · Cited by 491
Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 485
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 474
Janus kinases: components of multiple signaling pathways
Rane, S. G., & Reddy, E. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203925 · Cited by 466
The composition and signaling of the IL-35 receptor are unconventional
Collison, L. W., Delgoffe, G. M., Guy, C. S., Vignali, K. M., Chaturvedi, V., Fairweather, D., Satoskar, A. R., Garcia, K. C., Hunter, C. A., Drake, C. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2227 · Cited by 450
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
Interleukin‐4‐ and interleukin‐13‐mediated host protection against intestinal nematode parasites
Finkelman, F. D., Shea‐Donohue, T., Morris, S. C., Gildea, L., Strait, R., Madden, K. B., Schopf, L., & Urban, J. F. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00192.x · Cited by 440
Vermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 437
Chemokine receptor homo- or heterodimerization activates distinct signaling pathways
Mellado, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.10.2497 · Cited by 432
Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
Brooks, A. J., Dai, W., O’Mara, M. L., Abankwa, D., Chhabra, Y., Pelekanos, R. A., Gardon, O., Tunny, K. A., Blucher, K. M., Morton, C. J., et al. (2014) · Science · doi:10.1126/science.1249783 · Cited by 418
Harrison, D. A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011205 · Cited by 417
Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution?
Campbell, L. L., & Polyak, K. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4914 · Cited by 416
Immune Response in Stat2 Knockout Mice
Park, C., Li, S., Cha, E., & Schindler, C. (2000) · Immunity · doi:10.1016/s1074-7613(00)00077-7 · Cited by 415
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence
Mallette, F. A., Gaumont-Leclerc, M.-F., & Ferbeyre, G. (2007) · Genes & Development · doi:10.1101/gad.1487307 · Cited by 406
Interleukin-10 Receptor Signaling through the JAK-STAT Pathway
Riley, J. K., Takeda, K., Akira, S., & Schreiber, R. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16513 · Cited by 398
Stat3 and Stat4: members of the family of signal transducers and activators of transcription.
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4806 · Cited by 397
Murray, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500419102 · Cited by 394
Activation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393
One Nucleotide in a κB Site Can Determine Cofactor Specificity for NF-κB Dimers
Leung, T. H., Hoffmann, A., & Baltimore, D. (2004) · Cell · doi:10.1016/j.cell.2004.08.007 · Cited by 392
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain
Saharinen, P., Takaluoma, K., & Silvennoinen, O. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3387-3395.2000 · Cited by 365
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
Li, Y., Li, P.-K., Roberts, M. J., Arend, R. C., Samant, R. S., & Buchsbaum, D. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.003 · Cited by 364
Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348 · cited 2×
“Different reports indicate involvement of importin α5 and α7 (158), importin α3 and α6 (limited to testis) (159), or a variety of importin αs (160).”
BackgroundSignaling pathways activated by the growth hormone receptor
Herrington, J. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(01)00423-4 · Cited by 335
The molecular regulation of Janus kinase (JAK) activation
Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A., & Varghese, L. N. (2014) · Biochemical Journal · doi:10.1042/bj20140712 · Cited by 326
Majoros, A., Platanitis, E., Kernbauer-Hölzl, E., Rosebrock, F., Müller, M., & Decker, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00029 · Cited by 325
Mesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30027-3 · Cited by 324
(1990) · PubMed · Cited by 322
Regulation of c-myc expression by IFN-γ through Stat1-dependent and -independent pathways
Ramana, C. V., Grammatikakis, N., Chernov, M., Nguyen, H., Chuan Goh, K., Williams, B. R. G., & Stark, G. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.2.263 · Cited by 319
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
The Jak-Stat pathway in normal and perturbed hematopoiesis
Ward, A. C., Touw, I., & Yoshimura, A. (2000) · Blood · doi:10.1182/blood.v95.1.19 · Cited by 313
Hülsmann, B. B., Labokha, A. A., & Görlich, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.019 · Cited by 310
JAK2, a third member of the JAK family of protein tyrosine kinases.
Harpur, A. G., Andres, A. ‐., Ziemiecki, A., Aston, R. R., & Wilks, A. F. (1992) · PubMed · Cited by 306
Canonical and non-canonical JAK–STAT signaling
Li, W. X. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.008 · Cited by 290
IFNγ signaling—Does it mean JAK–STAT?
Gough, D. J., Levy, D. E., Johnstone, R. W., & Clarke, C. J. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.004 · Cited by 289
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling
Frank, D. A., Mahajan, S., & Ritz, J. (1999) · Nature Medicine · doi:10.1038/7445 · Cited by 287
Structures and biological functions of IL-31 and IL-31 receptors
Zhang, Q., Putheti, P., Zhou, Q., Liu, Q., & Gao, W. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.003 · Cited by 287
The Role of STATs in Apoptosis
Battle, T., & Frank, D. (2002) · Current Molecular Medicine · doi:10.2174/1566524023362456 · Cited by 284
Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C.-F., Neubert, T. A., Skoda, R. C., Hubbard, S. R., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2099 · Cited by 276
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
Zhao, D., Pan, C., Sun, J., Gilbert, C., Drews-Elger, K., Azzam, D. J., Picon-Ruiz, M., Kim, M., Ullmer, W., El-Ashry, D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.257 · Cited by 267
IL-28 and IL-29: Newcomers to the interferon family
Uzé, G., & Monneron, D. (2007) · Biochimie · doi:10.1016/j.biochi.2007.01.008 · Cited by 260
CD80, CD86 and CD40 Provide Accessory Signals in a Multiple‐Step T‐Cell Activation Model
Van Gool, S. W., Vandenberghe, P., Boer, M. D., & Ceuppens, J. L. (1996) · Immunological Reviews · doi:10.1111/j.1600-065x.1996.tb00920.x · Cited by 257
Cooperation between STAT3 and c-Jun Suppresses Fas Transcription
Ivanov, V. N., Bhoumik, A., Krasilnikov, M., Raz, R., Owen-Schaub, L. B., Levy, D., Horvath, C. M., & Ronai, Z. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00199-x · Cited by 248
Vignais, M.-L., Sadowski, H. B., Watling, D., Rogers, N. C., & Gilman, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1759 · Cited by 248
Molecular Pathways: Adiponectin and Leptin Signaling in Cancer
VanSaun, M. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0930 · Cited by 246
Mutation in the Jak Kinase JH2 Domain Hyperactivates Drosophila and Mammalian Jak-Stat Pathways
Luo, H., Rose, P., Barber, D., Hanratty, W. P., Lee, S., Roberts, T. M., D’Andrea, A. D., & Dearolf, C. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1562 · Cited by 242
The Role of chemokine receptor CXCR4 in breast cancer metastasis.
Mukherjee, D., & Zhao, J. (2013) · Europe PMC (PubMed Central) · Cited by 235
Miyoshi, K., Takaishi, M., Nakajima, K., Ikeda, M., Kanda, T., Tarutani, M., Iiyama, T., Asao, N., DiGiovanni, J., & Sano, S. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.255 · Cited by 235
Leptin signaling in breast cancer: An overview
Cirillo, D., Rachiglio, A. M., la Montagna, R., Giordano, A., & Normanno, N. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21911 · Cited by 235
Santos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J., & Verstovsek, S. (2010) · Blood · doi:10.1182/blood-2009-10-246363 · Cited by 233
Kavanaugh, A., Kremer, J., Ponce, L., Cseuz, R., Reshetko, O. V., Stanislavchuk, M., Greenwald, M., Van der Aa, A., Vanhoutte, F., Tasset, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210105 · Cited by 229
Jatiani, S. S., Baker, S. J., Silverman, L. R., & Reddy, E. P. (2010) · Genes & Cancer · doi:10.1177/1947601910397187 · Cited by 228
A unique role for IL-23 in promoting cellular immunity
Lankford, C. S. R., & Frucht, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602326 · Cited by 211
Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes
Kotenko, S. V., & Pestka, S. (2000) · Oncogene · doi:10.1038/sj.onc.1203524 · Cited by 205
Erythropoietin receptor and interleukin-2 receptor β chain: A new receptor family
D'Andrea, A. D., Fasman, G. D., & Lodish, H. F. (1989) · Cell · doi:10.1016/0092-8674(89)90499-6 · Cited by 204
Friedmann, M. C., Migone, T. S., Russell, S. M., & Leonard, W. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.2077 · Cited by 203
Gao, H., Priebe, W., Glod, J., & Banerjee, D. (2009) · Stem Cells · doi:10.1002/stem.23 · Cited by 202
Briscoe, J., Rogers, N. C., Witthuhn, B. A., Watling, D., Harpur, A. G., Wilks, A. F., Stark, G. R., Ihle, J. N., & Kerr, I. M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00415.x · Cited by 194
Mechanism of Activation of the GM‐CSF, IL‐3, and IL‐5 Family of Receptors
Guthridge, M. A., Stomski, F. C., Thomas, D., Woodcock, J. M., Bagley, C. J., Berndt, M. C., & Lopez, A. F. (1998) · STEM CELLS · doi:10.1002/stem.160301 · Cited by 192
Fan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192
STAT6‐dependent and ‐independent mechanisms in Th2 polarization
Maier, E., Duschl, A., & Horejs‐Hoeck, J. (2012) · European Journal of Immunology · doi:10.1002/eji.201242433 · Cited by 181
Yang, C. H., Yue, J., Fan, M., & Pfeffer, L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2579 · Cited by 179
Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability
Royer, Y., Staerk, J., Costuleanu, M., Courtoy, P. J., & Constantinescu, S. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501376200 · Cited by 176
STAT5-Dependent CyclinD1 and Bcl-xL Expression in Bcr-Abl-Transformed Cells
de Groot, R. P., Raaijmakers, J. A. M., Lammers, J. J., & Koenderman, L. (2000) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.2000.0231 · Cited by 172
Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells
Huang, S., Bucana, C. D., Arsdall, M. V., & Fidler, I. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205341 · Cited by 172
Andoh, A., Shioya, M., Nishida, A., Bamba, S., Tsujikawa, T., Kim‐Mitsuyama, S., & Fujiyama, Y. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804169 · Cited by 169
Structural basis of recognition of interferon-α receptor by tyrosine kinase 2
Wallweber, H. J. A., Tam, C., Franke, Y., Starovasnik, M. A., & Lupardus, P. J. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2807 · Cited by 165
Korpelainen, E., Karkkainen, M. J., Gunji, Y., Vikkula, M., & Alitalo, K. K. (1999) · Oncogene · doi:10.1038/sj.onc.1202288 · Cited by 165
Mertens, C., Zhong, M., Krishnaraj, R., Zou, W., Chen, X., & Darnell, J. E. (2006) · Genes & Development · doi:10.1101/gad.1485406 · Cited by 164
Mucin-interacting proteins: from function to therapeutics
Senapati, S., Das, S., & Batra, S. K. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.10.003 · Cited by 161
Bernabei, P., Coccia, E. M., Rigamonti, L. M., Bosticardo, M., Forni, G., Pestka, S., Krause, C. D., Battistini, A., & Novelli, F. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.70.6.950 · Cited by 160
SOCS1 Links Cytokine Signaling to p53 and Senescence
Calabrese, V., Mallette, F. A., Deschênes‐Simard, X., Ramanathan, S., Gagnon, J., Moores, A., Ilangumaran, S., & Ferbeyre, G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.044 · Cited by 159
Wurster, A. L., Rodgers, V. L., White, M. F., Rothstein, T. L., & Grusby, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201207200 · Cited by 158
Activating STAT6 mutations in follicular lymphoma
Yildiz, M., Li, H., Bernard, D., Amin, N. A., Ouillette, P. D., Jones, S., Saiya-Cork, K., Parkin, B. L., Jacobi, K., Shedden, K., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582650 · Cited by 158
STAT5‐induced Id‐1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPβ
Xu, M. J., Nie, L., Kim, S., & Sun, X. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg094 · Cited by 157
Papp, K. A., Krueger, J. G., Feldman, S. R., Langley, R. G. B., Thaçi, D., Torii, H., Tyring, S. K., Wolk, R. A., Gardner, A., Mebus, C., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.013 · Cited by 157
Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival
Liu, H., Ma, Y., Cole, S. M., Zander, C., Chen, K.-H., Karras, J., & Pope, R. M. (2003) · Blood · doi:10.1182/blood-2002-11-3396 · Cited by 155
Leptin-Induced JAK/STAT Signaling and Cancer Growth
Mullen, M., & Gonzalez-Perez, R. R. (2016) · Vaccines · doi:10.3390/vaccines4030026 · Cited by 155
Banninger, G. P., & Reich, N. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400815200 · Cited by 154
Wong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. J., Wang, L. Z., Thuya, W. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv026 · Cited by 153
Therapeutic Targeting of the JAK / STAT Pathway
Aittomäki, S., & Pesu, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12164 · Cited by 152
Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., & Kaneko, Y. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208279 · Cited by 152
Campbell, C. L., Jiang, Z., Savarese, D. M. F., & Savarese, T. M. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63940-5 · Cited by 151
Reich, N. C. (2013) · JAK-STAT · doi:10.4161/jkst.27080 · Cited by 151
Targeting the JAK2/STAT3 axis in Alzheimer's disease
Chiba, T., Yamada, M., & Aiso, S. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903213426 · Cited by 147
Andl, C. D., Mizushima, T., Oyama, K., Bowser, M., Nakagawa, H., & Rustgi, A. K. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00253.2004 · Cited by 146
Ma, J., & Cao, X. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.06.016 · Cited by 144
IFITM1 plays an essential role in the antiproliferative action of interferon-γ
Yang, G., Xu, Y., Chen, X., & Hu, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209807 · Cited by 139
Bernabei, P., Coccia, E. M., Rigamonti, L., Bosticardo, M., Forni, G., Pestka, S., Krause, C. D., Battistini, A., & Novelli, F. (2001) · PubMed · Cited by 133
Martinez-Moczygemba, M., Gutch, M. J., French, D. L., & Reich, N. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.20070 · Cited by 132
The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils
Pazdrak, K., Stafford, S. J., & Alam, R. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.397 · Cited by 130
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Oh, D., Lee, S., Han, S., Kim, M., Kim, T.-M., Kim, T., Heo, D. S., Yuasa, M., Yanagihara, Y., & Bang, Y. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.249 · Cited by 128
STAT1-induced Apoptosis Is Mediated by Caspases 2, 3, and 7
Sironi, J., & Ouchi, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307774200 · Cited by 126
Malinge, S., Abdelali, R. B., Settegrana, C., Radford‐Weiss, I., Debré, M., Beldjord, K., Macintyre, E. A., Villeval, J., Vainchenker, W., Berger, R., et al. (2006) · Blood · doi:10.1182/blood-2006-09-045963 · Cited by 126
Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Baffert, F., Régnier, C. H., Pover, A. D., Pissot‐Soldermann, C., Tavares, G., Blasco, F., Brueggen, J., Chêne, P., Drueckes, P., Erdmann, D., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0053 · Cited by 126
Autocrine Regulation of IL-21 Production in Human T Lymphocytes
Caprioli, F., Sarra, M., Caruso, R., Stolfi, C., Fina, D., Sica, G. S., MacDonald, T. T., Pallone, F., & Monteleone, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1800 · Cited by 124
Kohanbash, G., & Okada, H. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.010 · Cited by 123
Bandapalli, O. R., Schuessele, S., Kunz, J. B., Rausch, T., Stütz, A. M., Tal, N., Geron, I., Gershman, N., Izraeli, S., Eilers, J., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.104992 · Cited by 123
A Network Map of FGF-1/FGFR Signaling System
Raju, R., Palapetta, S. M., Sandhya, V. K., Sahu, A., Alipoor, A., Balakrishnan, L., Advani, J., George, B., Kini, K. R., Geetha, N. P., et al. (2014) · Journal of Signal Transduction · doi:10.1155/2014/962962 · Cited by 123
Ogata, N., Kouro, T., Yamada, A., Koike, M., Hanai, N., Ishikawa, T., & Takatsu, K. (1998) · Blood · doi:10.1182/blood.v91.7.2264 · Cited by 118
The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective?
Ivashkiv, L., & Hu, X.-Y. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11095 · Cited by 118
Madamanchi, N. R., Li, S., Patterson, C., & Runge, M. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008802200 · Cited by 117
Mercher, T., Wernig, G., Moore, S. A., Levine, R. L., Gu, T.-L., Fröhling, S., Cullen, D., Polakiewicz, R. D., Bernard, O., Boggon, T. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-014712 · Cited by 116
Dudka, A. A., Sweet, S. M. M., & Heath, J. K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3033 · Cited by 116
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Plimack, E. R., LoRusso, P. M., Mccoon, P. E., Tang, W., Krebs, A. D., Curt, G. A., & Eckhardt, S. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0198 · Cited by 115
de Totero, D., Meazza, R., Zupo, S., Cutrona, G., Matis, S., Colombo, M., Balleari, E., Pierri, I., Fabbi, M., Capaia, M., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3535 · Cited by 115
Fleischmann, R., DAMJANOV, N. S., Kivitz, A., Legedza, A. K., Hoock, T. C., & Kinnman, N. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38949 · Cited by 114
Dalwadi, H., Krysan, K., Heuzé‐Vourc'h, N., Dohadwala, M., Elashoff, D. A., Sharma, S. P., Cacalano, N. A., Lichtenstein, A. K., & Dubinett, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1205 · Cited by 110
Full house: 12 receptors for 27 cytokines
Kotenko, S. V., & Langer, J. A. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.01.003 · Cited by 109
The multiple roles of Id-1 in cancer progression
Ling, M., Wang, X., Zhang, X., & Wong, Y. C. (2006) · Differentiation · doi:10.1111/j.1432-0436.2006.00083.x · Cited by 109
Identification of Novel IL-4/Stat6-Regulated Genes in T Lymphocytes
Chen, Z. J., Lund, R., Aittokallio, T. A., Kosonen, M., Nevalainen, O., & Lahesmaa, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3627 · Cited by 108
Kim, M. S., Lee, W. S., Jeong, J., Kim, S., & Jin, W. (2015) · Oncotarget · doi:10.18632/oncotarget.5522 · Cited by 108
Evolution of the JAK-STAT pathway
Liongue, C., & Ward, A. C. (2013) · JAK-STAT · doi:10.4161/jkst.22756 · Cited by 106
Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia
Bellanger, D., Jacquemin, V., Chopin, M., Pierron, G., Bernard, O., Ghysdael, J., & Stern, M. (2013) · Leukemia · doi:10.1038/leu.2013.271 · Cited by 105
Subramaniam, P. S., Torres, B. A., & Johnson, H. M. (2001) · Cytokine · doi:10.1006/cyto.2001.0905 · Cited by 105
Ju, H., Venema, V. J., Liang, H., Harris, M. B., Zou, R., & Venema, R. C. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510257 · Cited by 104
A pathway map of prolactin signaling
Radhakrishnan, A., Raju, R., Tuladhar, N., Subbannayya, T., Thomas, J. K., Goel, R., Telikicherla, D., Palapetta, S. M., Rahiman, B. A., Desai, D. V., et al. (2012) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-012-0168-0 · Cited by 101
Battle, T. E., Lynch, R. A., & Frank, D. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3612 · Cited by 101
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Gupta, V. K., Mesa, R. A., Deininger, M. W., Rivera, C. E., Sirhan, S., Brachmann, C. B., Collins, H., Kawashima, J., Xin, Y., & Verstovšek, S. (2016) · Haematologica · doi:10.3324/haematol.2016.148924 · Cited by 101
Stat3 promotes directional cell migration by regulating Rac1 activity via its activator βPIX
Teng, T., Lin, B., Manser, E., Ng, D. C. H., & Cao, X. (2009) · Journal of Cell Science · doi:10.1242/jcs.057109 · Cited by 99
Behrmann (2004) · doi:10.1074/jbc.m404202200 · Cited by 98
EGFR–STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors
Wu, J., Patmore, D. M., Jousma, E., Eaves, D. W., Breving, K., Patel, A. V., Schwartz, E. B., Fuchs, J. R., Cripe, T. P., Stemmer-Rachamimov, A. O., et al. (2013) · Oncogene · doi:10.1038/onc.2012.579 · Cited by 96
Creamer, B. A., Sakamoto, K., Schmidt, J. W., Triplett, A. A., Moriggl, R., & Wagner, K. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00851-09 · Cited by 96
Park, J., Lee, J. J., Lim, M., Kim, E., Kim, S.-M., Ryu, J.-G., Lee, J. H., Kwok, S.-K., Park, K.-S., Kim, H., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300514 · Cited by 95
HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer
Rath, K. S., Naidu, S. K., Lata, P., Bid, H. K., Rivera, B. K., McCann, G. A., Tierney, B. J., ElNaggar, A. C., Bravo, V., Leone, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2433 · Cited by 95
Nucleocytoplasmic shuttling of persistently activated STAT3
Herrmann, A., Vogt, M., Mönnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., & Müller-Newen, G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03482 · Cited by 94
Sonier, B., Arseneault, M., Lavigne, C., Ouellette, R. J., & Vaillancourt, C. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.080 · Cited by 94
Cited by
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
Zhu, H., Jian, Z., Zhong, Y., Ye, Y., Zhang, Y., Hu, X., Pu, B., Gu, L., & Xiong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714943 · Cited by 370
Metadata
- Authors
- Bousoik, E., & Montazeri Aliabadi, H.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-31
- Volume
- 8
- Pages
- 287-287
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2886980930
- Cited by
- 376
- References
- 283
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.